Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Belshe

Showing results (61-70 of 143) with videos related to

Pageof 15
Sort By:
Southern Medical Journal|October 1, 1985
Fatal coxsackievirus B4 infection in a neonateE R Porres, J Werthammer, N Moss, et al.
The Journal of Infectious Diseases|May 1, 1994
Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination scheduleT U Westblom, S Gudipati, C DeRousse, et al.
Journal of Clinical Microbiology|January 1, 1991
A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988M A Mufson, B Akerlind-Stopner, C Orvell, et al.
The Journal of Infectious Diseases|March 1, 1989
Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillanceR B Belshe, B Burk, F Newman, et al.
AIDS (London, England)|August 10, 2000
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation GroupS Sabbaj, M J Mulligan, R H Hsieh, et al.
Vaccine|September 1, 1995
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, G B Patel, F K Newman, et al.
AIDS Research and Human Retroviruses|July 17, 1999
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation GroupG J Gorse, G B Patel, M Mandava, et al.
Vaccine|August 1, 1994
Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, S E Frey, G Patel, et al.
Journal of Clinical Microbiology|February 1, 1994
Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassayR A Karron, J L Froehlich, L Bobo, et al.
Journal of Virology|May 1, 1988
Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infectionR B Belshe, M H Smith, C B Hall, et al.
Pageof 15

Showing results (61-70 of 143) with videos related to

Sort By:
Pageof 15
Southern Medical Journal|October 1, 1985
Fatal coxsackievirus B4 infection in a neonateE R Porres, J Werthammer, N Moss, et al.
The Journal of Infectious Diseases|May 1, 1994
Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination scheduleT U Westblom, S Gudipati, C DeRousse, et al.
Journal of Clinical Microbiology|January 1, 1991
A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988M A Mufson, B Akerlind-Stopner, C Orvell, et al.
The Journal of Infectious Diseases|March 1, 1989
Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillanceR B Belshe, B Burk, F Newman, et al.
AIDS (London, England)|August 10, 2000
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation GroupS Sabbaj, M J Mulligan, R H Hsieh, et al.
Vaccine|September 1, 1995
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, G B Patel, F K Newman, et al.
AIDS Research and Human Retroviruses|July 17, 1999
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation GroupG J Gorse, G B Patel, M Mandava, et al.
Vaccine|August 1, 1994
Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, S E Frey, G Patel, et al.
Journal of Clinical Microbiology|February 1, 1994
Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassayR A Karron, J L Froehlich, L Bobo, et al.
Journal of Virology|May 1, 1988
Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infectionR B Belshe, M H Smith, C B Hall, et al.
Pageof 15